HAINAN SHUANGCHENG PHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.02 CNY | +3.08% |
|
+2.87% | -33.16% |
| Mar. 18 | Hainan Shuangcheng Pharma's Unit Gets Green Light to Market Pregabalin Capsules | MT |
| Mar. 15 | Shuangcheng Pharmaceutical Gets Nod to Market Anticoagulant in Saudi Arabia | MT |
| Sales 2021 | 320M 44.2M | Sales 2022 | 275M 37.92M | Capitalization | 3.02B 416M |
|---|---|---|---|---|---|
| Net income 2021 | -20M -2.76M | Net income 2022 | 9M 1.24M | EV / Sales 2021 | 6.35 x |
| Net Debt 2021 | 89.98M 12.42M | Net Debt 2022 | 77.35M 10.68M | EV / Sales 2022 | 11.3 x |
| P/E ratio 2021 |
-94.4
x | P/E ratio 2022 |
364
x | Employees | 414 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 49.56% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.08% | ||
| 1 week | +2.87% | ||
| Current month | -19.16% | ||
| 1 month | -19.68% | ||
| 3 months | -20.57% | ||
| 6 months | -28.69% | ||
| Current year | -33.16% |
1 week
4.53
5.24
1 month
4.536.78
Current year
3.677.76
1 year
3.679.72
3 years
3.6711.95
5 years
3.4111.95
10 years
3.4121.62
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Ming Li
CEO | Chief Executive Officer | 68 | 13-06-30 |
Xu Guang Wang
DFI | Director of Finance/CFO | 56 | 05-07-31 |
Cheng Dong Wang
CHM | Chairman | 71 | 00-05-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheng Dong Wang
CHM | Chairman | 71 | 00-05-21 |
Ying Pu Wang
BRD | Director/Board Member | 43 | 07-12-31 |
Jian Lin Yuan
BRD | Director/Board Member | 51 | 03-01-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 5.04 | +0.40% | 11,733,600 |
| 24-04-25 | 5.02 | +3.08% | 14,795,500 |
| 24-04-24 | 4.87 | +0.83% | 5,931,300 |
| 24-04-23 | 4.83 | +4.09% | 7,757,600 |
| 24-04-22 | 4.64 | -2.93% | 9,144,400 |
End-of-day quote Shenzhen S.E., April 24, 2024
More quotes
Hainan Shuangcheng Pharmaceuticals Co., Ltd. is a China-based company principally engaged in the production, sale, research and development of chemically synthesized peptide drugs. The Company's main products include Jitai (thymalfasin for injection), for the treatment of various types of liver diseases, cancers, geriatric deseases and infectious diseases; thymopentin for infection; somatostatin, for the treatment of severe acute esophageal variceal bleeding and severe acute stomach or for the adjuvant therapy of duodenal ulcer bleeding and diabetic ketoacidosis, as well as other drugs. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.16% | 289M | |
| +19.62% | 43.78B | |
| +20.44% | 21.89B | |
| +10.98% | 14.45B | |
| +13.07% | 13.63B | |
| +37.46% | 11.49B | |
| -8.59% | 6.85B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.35% | 5.06B |
- Stock Market
- Equities
- 002693 Stock
